Energy · Oil & Gas Field Services, NEC

CLB Core Laboratories Inc. /DE/ SEC Filings & Insider Trading Activity 2026

company
CIK 195808648 filings
Russell 2000

CLB at a glance

Core Laboratories Inc. /DE/ (CLB, SEC CIK 1958086) filed its latest 10-K annual report on March 23, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on October 28, 2026 and Form 4 insider filings as recently as October 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Core Laboratories Inc. /DE/ (CLB) reported revenue of $526.5 million (up 0.5% from FY2024) and net income of $29.7 million. Diluted EPS was $0.63.
  • As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Core Laboratories Inc. /DE/ (CLB) shares worth $166.7 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$526.5M
+0.5% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
26 funds
$166.7M · −1 vs prior quarter
Latest 8-K
Oct 28, 2026
Item 2.02 · Item 7.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $132.1M, down 2% YoY from $134.5M
  • Net income $5.5M, 4% margin vs 11% YoY; operating margin 9% vs 16%
  • Best segment: Production Enhancement revenue $47.8M, up 3%, margin 9%; Reservoir Description revenue $84.3M, down 4%, margin 9% vs 19%
  • Cash $21.4M vs $22.7M at December 31, 2025; operating cash flow $16.7M for nine months vs $29.1M
  • Capital deployment: $14.4M capital expenditures, $7.7M share repurchases, $1.4M dividends; geopolitical conflicts and sanctions driving near-term volatility

Risk Factors

  • No material changes disclosed from the December 31, 2025 Form 10-K risk factors
  • Business performance risk: known or unknown risks could materially affect operations, financial position, or results
  • Information risk: currently immaterial or unknown risks may impair business operations

AI summary of the CLB 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 28, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Third-quarter 2026 earnings release, providing the latest operating and financial update for Core Laboratories
  • Full results and management commentary contained in the October 28, 2026 press-release exhibit

Item 7.01: Regulation FD Disclosure

  • Quarterly cash dividend maintained at $0.01 per share
  • Shareholder record date: November 9, 2026

Item EX-99.1: Item EX-99.1

  • Q3 revenue $132.1M, up 6% sequentially but down 2% year-over-year, signaling recovery without full demand normalization
  • Ex-items EPS $0.16, up 46% sequentially but down 27% year-over-year, with operating margin near 10%
Filed Aug 25, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Director Kwaku Temeng resigning effective October 1, 2026
  • Resignation reflects disagreement over strategic direction and governance practices
Filed Jul 29, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results announced on July 29, 2026
  • Earnings details and operating performance contained in the accompanying press release exhibit

Item 7.01: Regulation FD Disclosure

  • Quarterly cash dividend of $0.01 per share announced
  • August 10, 2026 record date; August 31, 2026 payment date

Item EX-99.1: Item EX-99.1

  • Q2 revenue $124.6M, down 4% YoY, while operating income $9.2M and EPS $0.13 reflected sequential recovery
  • Production Enhancement drove momentum, with revenue up 15% sequentially to $45.9M and operating income up 550% sequentially to $5.2M

AI summaries of CLB 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CLB

Don't miss the next CLB filing

  • Alerts as it files. A push when CLB files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CLB, by share count.
  • Ask anything. An AI agent that reads every CLB filing and answers with sources.

CLB alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Teo Sow HangMOct 1, 2026-
Tattoli Mark DamianFOct 1, 2026$9.76
Tattoli Mark DamianMOct 1, 2026-
Teo Sow HangMOct 1, 2026-
Teo Sow HangFOct 1, 2026$9.76
Tattoli Mark DamianMOct 1, 2026-
Teo Sow HangMAug 1, 2026-
Teo Sow HangFAug 1, 2026$10.64

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$523.8M$526.5M
Operating Income-$58.6M$56.5M
Net Income$36.7M$31.4M$29.7M
Op. Margin-11.2%10.7%
Net Margin-6.0%5.6%
Balance Sheet
Total Assets-$590.4M$584.0M
Equity$224.8M$252.0M$266.0M
ROE16.3%12.5%11.2%
Per Share
EPS$0.77$0.66$0.63
Cash Flow
Operating CF-$56.4M$37.0M
CapEx$10.6M$13.0M$11.2M

Source: XBRL data in Core Laboratories Inc. /DE/ (CLB)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CLB share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CLB shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202626$166.7M
Q2 202627$213.0M
Q1 202628$291.7M
Q4 202526$278.8M
Q3 202529$217.4M
Q2 202527$219.1M
Q1 202525$176.2M
Q4 202421$193.4M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers

Source: 13F-HR filings on SEC EDGAR (aggregated from 209 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CLB filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QOct 30, 2026Analysis
8-KOct 28, 2026Analysis-
4Oct 5, 2026--
4Oct 5, 2026--
8-KAug 25, 2026Analysis-
4Aug 4, 2026--
4Aug 4, 2026--
4Aug 4, 2026--
10-QJul 30, 2026Analysis
8-KJul 29, 2026Analysis-
8-KMay 13, 2026Analysis
4May 4, 2026--
10-QMay 1, 2026Analysis
8-KApr 29, 2026Analysis-
4Apr 8, 2026--
4Apr 7, 2026--
4Apr 7, 2026--
4Apr 7, 2026--
4Apr 7, 2026--
4Apr 7, 2026--
8-KMar 23, 2026--
10-KMar 23, 2026-
8-KMar 17, 2026Analysis-
8-KMar 5, 2026Analysis-
4Feb 17, 2026-

Related Energy companies

All Energy →

CLB SEC filings: frequently asked questions

Which institutions hold CLB stock?

As of September 30, 2026, the largest Core Laboratories Inc. /DE/ (CLB) holders among the 13F filers tracked by SignalX were BlackRock ($43.8 million), Dimensional Fund Advisors ($15.7 million), Vanguard Capital Management LLC ($15.3 million), State Street Corp ($15.1 million), D.E. Shaw & Co ($13.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was CLB's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Core Laboratories Inc. /DE/ (CLB) reported revenue of $526.5 million (up 0.5% from FY2024) and net income of $29.7 million. Diluted EPS was $0.63. The figures come from the XBRL data in the 10-K.

What did CLB report in its latest 8-K?

Core Laboratories Inc. /DE/ (CLB) filed an 8-K on October 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Third-quarter 2026 earnings release, providing the latest operating and financial update for Core Laboratories.

What are the latest CLB SEC filings?

Core Laboratories Inc. /DE/ (CLB) filed its latest 10-K annual report on March 23, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on October 28, 2026 and a Form 4 insider filing on October 5, 2026.

What is CLB's SEC CIK number?

Core Laboratories Inc. /DE/ (CLB)'s SEC Central Index Key (CIK) is 1958086. EDGAR lists every CLB filing under that number.

Ask anything about CLB

The research agent reads CLB's filings, financials, insider trades and 13F holders, then answers with sources.